会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 32. 发明授权
    • System and method for assessing data quality during clinical trials
    • 在临床试验中评估数据质量的系统和方法
    • US08682685B2
    • 2014-03-25
    • US11577681
    • 2006-02-10
    • David P. Katz
    • David P. Katz
    • G06Q99/00G06Q50/00A61B5/00G06F19/00
    • G06F19/363G06F19/00G06Q10/06393G06Q10/06395G06Q50/22G16H10/20
    • The present invention relates to a system and methods for facilitating the improvement of data quality generated during drug and medical device clinical trials. In one embodiment, the invention includes a system and method for generating an ideal subject suitability score for one or more interaction points of a clinical trial. One or more individual subject suitability scores may then be generated from actual subject interaction with the clinical trial for each of the interaction points of the clinical trial. For each interaction point for which an ideal subject suitability score is generated, the one or more individual subject suitability scores may be compared to the ideal subject suitability score to determine the deviation there between. The quality of data collected from actual subject interaction with the clinical trial may be a function of the difference between the individual and ideal subject suitability scores.
    • 本发明涉及一种用于促进改善在药物和医疗装置临床试验期间产生的数据质量的系统和方法。 在一个实施方案中,本发明包括用于产生临床试验的一个或多个相互作用点的理想受试者适宜性评分的系统和方法。 然后可以从与临床试验的每个相互作用点的临床试验的实际受试者相互作用产生一个或多个个体受试者适宜性评分。 对于产生理想受试者适合度得分的每个相互作用点,可以将一个或多个个体受试者适合度得分与理想受试者适宜性评分进行比较,以确定其间的偏差。 从实际受试者与临床试验相互作用收集的数据的质量可能是个体和理想受试者适宜性评分之间的差异的函数。
    • 34. 发明申请
    • PATIENT-INTERACTIVE HEALTHCARE MANAGEMENT
    • 患者交互式健康管理
    • US20130332189A1
    • 2013-12-12
    • US13968488
    • 2013-08-16
    • CarePartners Plus
    • Michael G. ManningMartha Jean Elizabeth Minniti
    • G06F19/00
    • G06F19/363G06F19/00G06Q30/01G06Q30/04G06Q50/22G16H10/20G16H40/20H04B7/1853H04M1/72522
    • Patient-interactive health care management provides the ability for healthcare services received by a patient to be confirmed by the patient, or designated person, immediately after and subsequently after the healthcare services are rendered. The patient/designated person may be provided the ability to verify the accuracy of an invoice for the rendered services/goods and may provide an assessment of the rendered services/goods. The patient/designated person may provide this information via an appropriate stationary and/or portable processor. Healthcare may be received at any appropriate location or locations. The evaluation may occur at any appropriate location or locations. An after care risk assessment may be provided to the patient/designated person to evaluate the patient's status immediately after, subsequently after, and/or in between the healthcare services rendered. Patient-interactive health care may protect the safety of patients, mitigate disparities in care, protect payers, and/or facilitate adoption of health information technology.
    • 患者互动的医疗保健管理提供患者接受的医疗保健服务的能力,由患者或指定的人在医疗服务提供之后和之后立即确认。 可以向患者/指定人员提供验证所提供的服务/货物的发票的准确性的能力,并且可以提供所提供的服务/商品的评估。 患者/指定人员可以通过适当的固定和/或便携式处理器来提供该信息。 可在任何适当的位置或位置接收医疗服务。 评估可能发生在任何适当的位置或位置。 可以向患者/指定人员提供后护理风险评估,以便在所提供的医疗服务之后,之后和/或之间立即评估患者的状态。 患者互动的医疗保健可以保护患者的安全,减轻护理的差距,保护付款人和/或促进卫生信息技术的采用。
    • 36. 发明申请
    • DESIGN ASISTANCE FOR CLINICAL TRIAL PROTOCOLS
    • 临床试验方案的设计援助
    • US20130226610A1
    • 2013-08-29
    • US13872460
    • 2013-04-29
    • Medidata Solutions, Inc.
    • Carol A. BrovermanPeter L. AbramowitschMichael G. KahnChristopher Noon
    • G06Q50/22
    • G06F19/363G06F17/30011G06F19/00G06F19/324G06Q10/067G06Q50/22G16H10/20
    • Roughly described, a user instantiates protocol elements in a structured clinical trial protocol database and then draws from them in the development of one or more protocol related documents. The system helps the user select tasks to be performed during the study by reference to a historical database of tasks previously associated with similar protocols. The system automatically generates complex content from protocol elements in the database, and can render overlapping sets of protocol elements differently at different locations in the document. The system can automatically provide advisories indicating aspects of the document that still require completion or highlighting other issues that a sponsoring authority deems important for the document type. After all protocol elements are instantiated in the protocol database, it can then be used to drive the operation of most downstream aspects of the study.
    • 粗略地描述,用户在结构化临床试验协议数据库中实例化协议元素,然后从它们中抽出开发一个或多个协议相关文档。 该系统帮助用户通过参考先前与类似协议相关联的任务的历史数据库来选择在研究期间执行的任务。 该系统自动从数据库中的协议元素生成复杂的内容,并且可以在文档的不同位置呈现不同的协议元素的重叠集合。 该系统可以自动提供指示文档方面的建议,该方面仍然需要完成,或突出显示赞助机构认为对文档类型重要的其他问题。 在协议数据库中实例化所有协议元素之后,它可以用于驱动研究的大多数下游方面的操作。
    • 37. 发明申请
    • SYSTEMS AND METHODS FOR DRUG DEVELOPMENT
    • 用于药物开发的系统和方法
    • US20130197894A1
    • 2013-08-01
    • US13751413
    • 2013-01-28
    • Tomasz Sablinski
    • Tomasz Sablinski
    • G06F19/00
    • G06F19/363G06F19/00G16H10/20
    • Systems and methods are provided for drug development under a fully transparent development model. The model is configured to provide transparency to the patients, the researchers, clinicians, physicians, and any other registered users of the system who wish to contribute. According to various embodiments, the system and model enable drug development that leverage the combined wisdom and insight of the user population eliminating many of the drawbacks of conventional development approaches. In one embodiment, the system includes drug development engine configured to manage execution of parameters of a clinical trial, including collection of health and treatment information from a patient population. The development engine can publish collected execution data for review and analysis.
    • 在完全透明的发展模式下,为药物开发提供了系统和方法。 该模型被配置为向患者,研究人员,临床医生,医生以及希望贡献的系统的任何其他注册用户提供透明度。 根据各种实施方案,该系统和模型使得能够利用用户群体的智慧和洞察力的药物开发消除了常规开发方法的许多缺点。 在一个实施例中,该系统包括被配置为管理临床试验参数的执行的药物开发引擎,包括从患者群体收集健康和治疗信息。 开发引擎可以发布收集的执行数据进行审查和分析。
    • 39. 发明申请
    • System and Method for Assessing Data Quality During Clinical Trials
    • 临床试验中数据质量评估的系统和方法
    • US20080109455A1
    • 2008-05-08
    • US11577681
    • 2006-02-10
    • David P. Katz
    • David P. Katz
    • G06F17/30
    • G06F19/363G06F19/00G06Q10/06393G06Q10/06395G06Q50/22G16H10/20
    • The present invention relates to a system and methods for facilitating the improvement of data quality generated during drug and medical device clinical trials. In one embodiment, the invention includes a system and method for generating an ideal subject suitability score for one or more interaction points of a clinical trial. One or more individual subject suitability scores may then be generated from actual subject interaction with the clinical trial for each of the interaction points of the clinical trial. For each interaction point for which an ideal subject suitability score is generated, the one or more individual subject suitability scores may be compared to the ideal subject suitability score to determine the deviation there between. The quality of data collected from actual subject interaction with the clinical trial may be a function of the difference between the individual and ideal subject suitability scores.
    • 本发明涉及一种用于促进改善在药物和医疗装置临床试验期间产生的数据质量的系统和方法。 在一个实施方案中,本发明包括用于产生临床试验的一个或多个相互作用点的理想受试者适宜性评分的系统和方法。 然后可以从与临床试验的每个相互作用点的临床试验的实际受试者相互作用产生一个或多个个体受试者适宜性评分。 对于产生理想受试者适合度得分的每个相互作用点,可以将一个或多个个体受试者适合度得分与理想受试者适宜性评分进行比较,以确定其间的偏差。 从实际受试者与临床试验相互作用收集的数据的质量可能是个体和理想受试者适宜性评分之间的差异的函数。
    • 40. 发明申请
    • Sample analyzer and sample analyzing method
    • 样品分析仪和样品分析方法
    • US20070111197A1
    • 2007-05-17
    • US11542312
    • 2006-10-03
    • Hideki Hirayama
    • Hideki Hirayama
    • C12Q1/00G06F19/00
    • G06F19/363G06F19/00G06Q50/24G16H10/20
    • A sample analyzer comprising: a measurement section for measuring a sample of an animal; a memory for storing a measurement data by the measurement section; an analysis section for analyzing the measurement data stored on the memory in accordance with a first analysis condition corresponding to a previous setting of a species of an animal; and a selection receiver for receiving a selection of a species of an animal, which is different from the species of the previous setting, after analyzing the measurement data by the analysis section; wherein the analysis section analyzes the measurement data stored on the memory in accordance with a second analysis condition corresponding to the selection of a species of an animal when the selection receiver receives the selection of a species of an animal, is disclosed. A sample analyzing method is also disclosed.
    • 一种样品分析仪,包括:用于测量动物样本的测量部分; 用于由测量部分存储测量数据的存储器; 分析部分,用于根据对应于动物物种的先前设置的第一分析条件来分析存储在存储器中的测量数据; 以及选择接收器,用于在通过分析部分分析测量数据之后接收与先前设置的种类不同的动物种类的选择; 其中所述分析部分在所述选择接收者接收到动物种类的选择时,根据对应于动物种类的选择的第二分析条件来分析存储在所述存储器中的测量数据。 还公开了一种样品分析方法。